Elekta AB (publ)

OTCPK:EKTA.F Stock Report

Market Cap: US$2.2b

Elekta Valuation

Is EKTA.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKTA.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EKTA.F ($5.42) is trading below our estimate of fair value ($9.85)

Significantly Below Fair Value: EKTA.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKTA.F?

Key metric: As EKTA.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EKTA.F. This is calculated by dividing EKTA.F's market cap by their current earnings.
What is EKTA.F's PE Ratio?
PE Ratio21.7x
EarningsSEK 1.13b
Market CapSEK 24.57b

Price to Earnings Ratio vs Peers

How does EKTA.F's PE Ratio compare to its peers?

The above table shows the PE ratio for EKTA.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67.1x
CNMD CONMED
18.2x13.8%US$2.3b
LMAT LeMaitre Vascular
58.3x12.2%US$2.4b
NUVA NuVasive
73.3x46.2%US$2.1b
LIVN LivaNova
118.7x48.1%US$2.8b
EKTA.F Elekta
21.7x17.9%US$24.6b

Price-To-Earnings vs Peers: EKTA.F is good value based on its Price-To-Earnings Ratio (21.7x) compared to the peer average (65x).

Price to Earnings Ratio vs Industry

How does EKTA.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.7xn/aUS$18.77m
PAVM PAVmed
0.7x-77.8%US$10.99m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
EKTA.F 21.7xIndustry Avg. 38.3xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EKTA.F is good value based on its Price-To-Earnings Ratio (21.7x) compared to the US Medical Equipment industry average (38.3x).

Price to Earnings Ratio vs Fair Ratio

What is EKTA.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKTA.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EKTA.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKTA.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.42
US$6.92
+27.7%
24.0%US$11.63US$5.22n/a14
Nov ’25n/a
US$7.17
0%
23.6%US$11.92US$5.35n/a14
Oct ’25n/a
US$7.41
0%
23.8%US$12.34US$5.54n/a14
Sep ’25US$6.70
US$7.50
+11.9%
24.7%US$12.42US$5.57n/a13
Aug ’25n/a
US$7.04
0%
24.9%US$11.72US$5.26n/a13
Jul ’25US$6.25
US$7.29
+16.7%
24.7%US$12.13US$5.44n/a13
Jun ’25n/a
US$7.88
0%
24.4%US$11.90US$5.34n/a12
May ’25n/a
US$7.78
0%
24.5%US$11.84US$5.31n/a12
Apr ’25n/a
US$8.41
0%
23.7%US$12.42US$5.58n/a12
Mar ’25US$7.22
US$8.37
+15.9%
23.4%US$12.31US$5.52n/a12
Feb ’25US$7.48
US$8.30
+11.0%
23.4%US$12.16US$5.46n/a12
Jan ’25US$8.15
US$8.08
-0.9%
23.3%US$12.10US$5.43n/a11
Dec ’24n/a
US$8.18
0%
23.7%US$12.24US$5.49n/a11
Nov ’24n/a
US$7.47
0%
26.2%US$11.57US$4.83n/a11
Oct ’24US$6.82
US$7.58
+11.1%
26.6%US$11.55US$4.82n/a10
Sep ’24US$7.02
US$7.58
+7.9%
26.6%US$11.55US$4.82US$6.7010
Aug ’24US$8.22
US$8.02
-2.5%
26.2%US$12.24US$5.49n/a10
Jul ’24n/a
US$7.97
0%
26.0%US$11.84US$5.32US$6.2510
Jun ’24n/a
US$7.68
0%
25.5%US$11.70US$5.25n/a10
May ’24US$8.34
US$7.84
-6.0%
28.3%US$12.25US$5.50n/a10
Apr ’24US$7.45
US$7.84
+5.2%
28.3%US$12.25US$5.50n/a10
Mar ’24US$7.63
US$7.50
-1.8%
28.7%US$12.22US$5.48US$7.229
Feb ’24US$7.27
US$7.04
-3.1%
31.5%US$12.14US$4.97US$7.489
Jan ’24US$6.06
US$6.81
+12.5%
31.8%US$12.28US$5.03US$8.159
Dec ’23US$6.10
US$6.99
+14.6%
32.5%US$12.20US$4.99n/a8
Nov ’23US$5.23
US$6.86
+31.4%
29.6%US$11.45US$4.96n/a8

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$61.43

7D

4.4%

1Y

-17.1%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$407.60

7D

1.7%

1Y

-14.6%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.35

7D

17.6%

1Y

102.0%